In a move reflecting boundless ambitions, billionaire Elon Musk expressed absolute confidence that Neuralink will ultimately be able to restore the sense of hearing in deaf individuals. This revolutionary technology relies on directly stimulating the auditory cortex in the brain, representing a qualitative leap in the field of neuro-medicine. These statements, published via the X platform in early April 2026, underscore the broadening scope of the brain-computer interface company’s goals, coinciding with the expansion of its operations and an increase in the scale of its human clinical trials.
From paralysis to restoring lost senses
This new direction toward restoring hearing represents a natural extension of the successes achieved by the company in its previous trials with paralysis patients, and builds upon the “Blindsight” chip implant project dedicated to restoring vision. In a previous post on the X platform during the summer of last year, Musk explained that the brain chip could help deaf people hear, even those born without the sense, by sending signals directly to the brain’s auditory processing center, thereby bypassing the ear and its complex structure entirely.
This mechanism closely resembles how the Blindsight implant works, where an external camera captures visual information and transmits it wirelessly to an implant placed in the visual cortex, enabling visual perception even in patients who have lost both eyes and the optic nerve completely. The Blindsight device received “breakthrough device” designation from the U.S. Food and Drug Administration in September 2024. Neuralink announced that it is preparing to begin the first human trials for this implant during 2026, pending final regulatory approvals. Although Musk warned that initial vision would be low-resolution, comparing it to old Atari graphics, he emphasized that it could eventually surpass natural human sight capabilities, including futuristic capabilities such as infrared and ultraviolet perception.
Expanding operations and mass production
Regarding the expansion of operations, Neuralink announced in January 2026 the enrollment of 21 participants in its current global trials, a notable increase compared to the 12 participants reported in September 2025, according to reports. Noland Arbaugh is the first recipient of this implant in January 2024, a quadriplegic patient who was able thanks to the chip to play video games, browse the internet, and control an on-screen mouse cursor using only his thoughts. The company proudly reported that no serious adverse events related to the device have been recorded in any of its trials to date.
By New Year’s Eve at the end of 2025, Musk announced via X that the company would begin “high-volume mass production” of brain-computer interface devices in 2026. This step is accompanied by a transition to a simplified and nearly fully automated surgical procedure relying on advanced surgical robots similar in precision and speed to modern sewing machines, aimed at connecting human brains to the internet seamlessly and safely. Thanks to this advanced robotic technology, the insertion time for ultra-fine neural threads is expected to drop to just 1.5 seconds per thread. To support these massive expansions, the company successfully raised $650 million in a Series E funding round in June 2025. Prominent names such as Ark Invest, Founders Fund, and Sequoia Capital participated in this investment round, in a deal that valued the company at approximately $9 billion.
New horizons beyond movement restoration
The company’s ambitions did not stop at restoring movement, vision, and hearing, but extended to restoring the ability to speak. In early 2026, a patient named Kenneth received an implant targeting the brain’s speech cortex, enabling the system to decode his imagined speech and convert it into audible speech on his behalf. This speech restoration device received medical breakthrough designation from the U.S. Food and Drug Administration in 2025.
These successive achievements represent not merely a medical-technical advancement, but herald a new dawn for all of humanity. With continuing trials now covering the restoration of movement, speech, and vision, and the upcoming inclusion of hearing on the near horizon, Neuralink is positioning itself as a comprehensive and leading platform in the field of neural restoration, although each new application faces its own set of technical and regulatory challenges that require diligent work to overcome. These steps confirm that neurotechnology is no longer science fiction, but has become a clinical reality being tested and developed successfully on the ground.
FAQs
Can the Neuralink chip restore hearing for the deaf?
Yes, Elon Musk expressed great confidence in the chip’s ability to restore the sense of hearing by sending neural signals directly to the auditory processing center in the brain, completely bypassing the ear even for individuals born deaf.
What is the “Blindsight” technology being developed by the company?
It is a revolutionary technology aimed at restoring vision using a camera that captures visual information and transmits it wirelessly to an implant in the brain’s visual cortex, allowing blind individuals or those missing the optic nerve to see again.
When will mass production of the company’s chips begin?
According to Elon Musk’s announcement at the end of 2025, the company will begin mass production of brain-computer interface devices during 2026, utilizing automated and extremely fast surgical procedures relying on precise robots.
Are there successful human trials so far?
Yes, most notably quadriplegic patient Noland Arbaugh, who received the chip in January 2024 and was able to use a computer with his thoughts, and more recently patient Kenneth, who received an implant that enabled him to restore the ability to speak in early 2026.
